• Genentech buys NASH biotech Jecure pharmaphorum
    November 30, 2018
    Roche’s Genentech unit has bought California biotech Jecure Therapeutics, which is researching drugs that could be used in inflammatory diseases including the fatty liver disease NASH.
  • Roche's Genentech to acquire inflammatory drug discovery firm Jecure pharmafile
    November 30, 2018
    Roche’s subsidiary Genentech has finalised a definitive agreement to acquire Jecure, a US-based biotech which focuses on the discovery of drugs to treat serious inflammatory conditions, in a bid to square up to rivals in the treatment of fatty liver disea
PharmaSources Customer Service